Cite
HARVARD Citation
Spencer, A. et al. (2018). A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results. British journal of haematology. pp. 41-51. [Online].